Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Phase 2 Unknown 30 enrolled Chinese Academy of Medical Sciences Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collab Peking University Cancer Hospital & Institute · collab The First Hospital of Jilin University · collab

NaSingle-groupOpen-labelTreatment

Summary

The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell lymphoma, nasal type

Timeline

Start: 2021-10-01
Primary completion: 2022-09-30
Completion: 2024-09-30

Publications

Li JY, Qi SN, Hu C, Liu X, Yang Y, Wu T, Zheng R, Feng XL, Ni XG, Jin FY, Song YQ, Liu WP, Zhou SY, Li YX. Tislelizumab and radiation therapy in low-risk early-stage extranodal natural killer/T-cell lymphoma, nasal type: a phase II study protocol. Future Oncol. 2024 Feb;20(5):245-256. doi: 10.2217/fon-2023-0065. Epub 2023 Nov 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tislelizumab	Monoclonal antibody	200 mg	—

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Summary

Timeline

Publications

Drugs

Indications